APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multiple Sclerosis (MS) Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Multiple Sclerosis (MS) Drugs Industry Growth and Trends Forecast to 2032

26 December 2025116 pages

Choose your research edition.

Industry ResearchMultiple Sclerosis (MS) Drugs Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Multiple Sclerosis (MS) Drugs Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Multiple Sclerosis (MS) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multiple Sclerosis (MS) Drugs Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Multiple Sclerosis (MS) Drugs Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Multiple Sclerosis (MS) Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Multiple Sclerosis (MS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Multiple Sclerosis (MS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Multiple Sclerosis (MS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Multiple Sclerosis (MS) Drugs include Eli Lilly, Bayer AG, Innate Immunotherapeutics, Gw Pharmaceuticals, Glaxosmithkline, Genzyme, Genmab, Five Prime Therapeutics and Fast Forward Llc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Multiple Sclerosis (MS) Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Multiple Sclerosis (MS) Drugs market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Multiple Sclerosis (MS) Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Multiple Sclerosis (MS) Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Multiple Sclerosis (MS) Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Multiple Sclerosis (MS) Drugs Market by Company

Eli Lilly

Bayer AG

Innate Immunotherapeutics

Gw Pharmaceuticals

Glaxosmithkline

Genzyme

Genmab

Five Prime Therapeutics

Fast Forward Llc

Daiichi Sankyo

Cinnagen

Biogen Idec

Bayhill Therapeutics

Artielle Immunotherapeutics

Apitope

Antisense Therapeutics

Multiple Sclerosis (MS) Drugs Segment by Type

Copaxone (Glatiramer Acetate, Copolymer 1)

Firategrast (Sb683699, T-0047)

Gilenya (Fingolimod, Fty720)

Tecfidera (Dimethyl Fumarate)

Aubagio (Teriflunomide)

Siponimod (Baf312)

Novantrone (Mitoxantrone)

Others

Multiple Sclerosis (MS) Drugs Segment by Application

PPMS

PRMS

RRMS

SPMS

Multiple Sclerosis (MS) Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multiple Sclerosis (MS) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multiple Sclerosis (MS) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multiple Sclerosis (MS) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Multiple Sclerosis (MS) Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Multiple Sclerosis (MS) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Copaxone (Glatiramer Acetate, Copolymer 1) Table 2. Major Company of Firategrast (Sb683699, T-0047) Table 3. Major Company of Gilenya (Fingolimod, Fty720) Table 4. Major Company of Tecfidera (Dimethyl Fumarate) Table 5. Major Company of Aubagio (Teriflunomide) Table 6. Major Company of Siponimod (Baf312) Table 7. Major Company of Novantrone (Mitoxantrone) Table 8. Major Company of Others Table 9. Global Multiple Sclerosis (MS) Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 10. Global Multiple Sclerosis (MS) Drugs Sales by Type (2021-2026) & (W Units) Table 11. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Type (2021-2026) Table 12. Global Multiple Sclerosis (MS) Drugs Sales by Type (2021-2026) & (US$ Million) Table 13. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Type (2021-2026) Table 14. Global Multiple Sclerosis (MS) Drugs Price by Type (2021-2026) & (US$/Unit) Table 15. Global Multiple Sclerosis (MS) Drugs Sales by Type (2027-2032) & (W Units) Table 16. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Type (2027-2032) Table 17. Global Multiple Sclerosis (MS) Drugs Sales by Type (2027-2032) & (US$ Million) Table 18. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Type (2027-2032) Table 19. Global Multiple Sclerosis (MS) Drugs Price by Type (2027-2032) & (US$/Unit) Table 20. North America Multiple Sclerosis (MS) Drugs Sales by Type (2021-2026) & (W Units) Table 21. North America Multiple Sclerosis (MS) Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Europe Multiple Sclerosis (MS) Drugs Sales by Type (2021-2026) & (W Units) Table 23. Europe Multiple Sclerosis (MS) Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales by Type (2021-2026) & (W Units) Table 25. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales by Type (2021-2026) & (US$ Million) Table 26. Latin America Multiple Sclerosis (MS) Drugs Sales by Type (2021-2026) & (W Units) Table 27. Latin America Multiple Sclerosis (MS) Drugs Sales by Type (2021-2026) & (US$ Million) Table 28. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Type (2021-2026) & (W Units) Table 29. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Type (2021-2026) & (US$ Million) Table 30. Multiple Sclerosis (MS) Drugs Industry Trends Table 31. Multiple Sclerosis (MS) Drugs Industry Drivers Table 32. Multiple Sclerosis (MS) Drugs Industry Opportunities and Challenges Table 33. Multiple Sclerosis (MS) Drugs Industry Restraints Table 34. Global Multiple Sclerosis (MS) Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 35. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Company (2021-2026) Table 36. Global Multiple Sclerosis (MS) Drugs Sales by Company (2021-2026) & (W Units) Table 37. Global Multiple Sclerosis (MS) Drugs Sales Share by Company (2021-2026) Table 38. Global Multiple Sclerosis (MS) Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 39. Global Multiple Sclerosis (MS) Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 40. Global Multiple Sclerosis (MS) Drugs Major Company Production Sites and Headquarters Table 41. Global Multiple Sclerosis (MS) Drugs Company, Product Type & Application Table 42. Global Multiple Sclerosis (MS) Drugs Company Establishment Date Table 43. Global Company Market Concentration Ratio (CR5 and HHI) Table 44. Global Multiple Sclerosis (MS) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 45. Global Multiple Sclerosis (MS) Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 46. Global Multiple Sclerosis (MS) Drugs Sales by Region (2021-2026) & (W Units) Table 47. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Region (2021-2026) Table 48. Global Multiple Sclerosis (MS) Drugs Sales by Region (2021-2026) & (US$ Million) Table 49. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Region (2021-2026) Table 50. Global Multiple Sclerosis (MS) Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Global Multiple Sclerosis (MS) Drugs Sales by Region (2027-2032) & (W Units) Table 52. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Region (2027-2032) Table 53. Global Multiple Sclerosis (MS) Drugs Sales by Region (2027-2032) & (US$ Million) Table 54. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Region (2027-2032) Table 55. Global Multiple Sclerosis (MS) Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 56. Global Multiple Sclerosis (MS) Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 57. Global Multiple Sclerosis (MS) Drugs Sales by Application (2021-2026) & (W Units) Table 58. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Application (2021-2026) Table 59. Global Multiple Sclerosis (MS) Drugs Sales by Application (2021-2026) & (US$ Million) Table 60. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Application (2021-2026) Table 61. Global Multiple Sclerosis (MS) Drugs Price by Application (2021-2026) & (US$/Unit) Table 62. Global Multiple Sclerosis (MS) Drugs Sales by Application (2027-2032) & (W Units) Table 63. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Application (2027-2032) Table 64. Global Multiple Sclerosis (MS) Drugs Sales by Application (2027-2032) & (US$ Million) Table 65. Global Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Application (2027-2032) Table 66. Global Multiple Sclerosis (MS) Drugs Price by Application (2027-2032) & (US$/Unit) Table 67. North America Multiple Sclerosis (MS) Drugs Sales by Application (2021-2026) & (W Units) Table 68. North America Multiple Sclerosis (MS) Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Europe Multiple Sclerosis (MS) Drugs Sales by Application (2021-2026) & (W Units) Table 70. Europe Multiple Sclerosis (MS) Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales by Application (2021-2026) & (W Units) Table 72. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales by Application (2021-2026) & (US$ Million) Table 73. Latin America Multiple Sclerosis (MS) Drugs Sales by Application (2021-2026) & (W Units) Table 74. Latin America Multiple Sclerosis (MS) Drugs Sales by Application (2021-2026) & (US$ Million) Table 75. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Application (2021-2026) & (W Units) Table 76. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Application (2021-2026) & (US$ Million) Table 77. Eli Lilly Company Information Table 78. Eli Lilly Business Overview Table 79. Eli Lilly Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Eli Lilly Multiple Sclerosis (MS) Drugs Product Portfolio Table 81. Eli Lilly Recent Development Table 82. Bayer AG Company Information Table 83. Bayer AG Business Overview Table 84. Bayer AG Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Bayer AG Multiple Sclerosis (MS) Drugs Product Portfolio Table 86. Bayer AG Recent Development Table 87. Innate Immunotherapeutics Company Information Table 88. Innate Immunotherapeutics Business Overview Table 89. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 91. Innate Immunotherapeutics Recent Development Table 92. Gw Pharmaceuticals Company Information Table 93. Gw Pharmaceuticals Business Overview Table 94. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Portfolio Table 96. Gw Pharmaceuticals Recent Development Table 97. Glaxosmithkline Company Information Table 98. Glaxosmithkline Business Overview Table 99. Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Portfolio Table 101. Glaxosmithkline Recent Development Table 102. Genzyme Company Information Table 103. Genzyme Business Overview Table 104. Genzyme Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Genzyme Multiple Sclerosis (MS) Drugs Product Portfolio Table 106. Genzyme Recent Development Table 107. Genmab Company Information Table 108. Genmab Business Overview Table 109. Genmab Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Genmab Multiple Sclerosis (MS) Drugs Product Portfolio Table 111. Genmab Recent Development Table 112. Five Prime Therapeutics Company Information Table 113. Five Prime Therapeutics Business Overview Table 114. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 116. Five Prime Therapeutics Recent Development Table 117. Fast Forward Llc Company Information Table 118. Fast Forward Llc Business Overview Table 119. Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Portfolio Table 121. Fast Forward Llc Recent Development Table 122. Daiichi Sankyo Company Information Table 123. Daiichi Sankyo Business Overview Table 124. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Portfolio Table 126. Daiichi Sankyo Recent Development Table 127. Cinnagen Company Information Table 128. Cinnagen Business Overview Table 129. Cinnagen Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Cinnagen Multiple Sclerosis (MS) Drugs Product Portfolio Table 131. Cinnagen Recent Development Table 132. Biogen Idec Company Information Table 133. Biogen Idec Business Overview Table 134. Biogen Idec Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Biogen Idec Multiple Sclerosis (MS) Drugs Product Portfolio Table 136. Biogen Idec Recent Development Table 137. Bayhill Therapeutics Company Information Table 138. Bayhill Therapeutics Business Overview Table 139. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 141. Bayhill Therapeutics Recent Development Table 142. Artielle Immunotherapeutics Company Information Table 143. Artielle Immunotherapeutics Business Overview Table 144. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 146. Artielle Immunotherapeutics Recent Development Table 147. Apitope Company Information Table 148. Apitope Business Overview Table 149. Apitope Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Apitope Multiple Sclerosis (MS) Drugs Product Portfolio Table 151. Apitope Recent Development Table 152. Antisense Therapeutics Company Information Table 153. Antisense Therapeutics Business Overview Table 154. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 156. Antisense Therapeutics Recent Development Table 157. North America Multiple Sclerosis (MS) Drugs Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 158. North America Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026) & (W Units) Table 159. North America Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2021-2026) Table 160. North America Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2027-2032) & (W Units) Table 161. North America Multiple Sclerosis (MS) Drugs Sales Market Share Forecast by Country (2027-2032) Table 162. North America Multiple Sclerosis (MS) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 163. North America Multiple Sclerosis (MS) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 164. North America Multiple Sclerosis (MS) Drugs Market Share by Country (2021-2026) Table 165. North America Multiple Sclerosis (MS) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 166. North America Multiple Sclerosis (MS) Drugs Market Share Forecast by Country (2027-2032) Table 167. Europe Multiple Sclerosis (MS) Drugs Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 168. Europe Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026) & (W Units) Table 169. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2021-2026) Table 170. Europe Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2027-2032) & (W Units) Table 171. Europe Multiple Sclerosis (MS) Drugs Sales Market Share Forecast by Country (2027-2032) Table 172. Europe Multiple Sclerosis (MS) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 173. Europe Multiple Sclerosis (MS) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 174. Europe Multiple Sclerosis (MS) Drugs Market Share by Country (2021-2026) Table 175. Europe Multiple Sclerosis (MS) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 176. Europe Multiple Sclerosis (MS) Drugs Market Share Forecast by Country (2027-2032) Table 177. Asia-Pacific Multiple Sclerosis (MS) Drugs Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 178. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026) & (W Units) Table 179. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2021-2026) Table 180. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2027-2032) & (W Units) Table 181. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Market Share Forecast by Country (2027-2032) Table 182. Asia-Pacific Multiple Sclerosis (MS) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 183. Asia-Pacific Multiple Sclerosis (MS) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 184. Asia-Pacific Multiple Sclerosis (MS) Drugs Market Share by Country (2021-2026) Table 185. Asia-Pacific Multiple Sclerosis (MS) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 186. Asia-Pacific Multiple Sclerosis (MS) Drugs Market Share Forecast by Country (2027-2032) Table 187. Latin America Multiple Sclerosis (MS) Drugs Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 188. Latin America Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026) & (W Units) Table 189. Latin America Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2021-2026) Table 190. Latin America Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2027-2032) & (W Units) Table 191. Latin America Multiple Sclerosis (MS) Drugs Sales Market Share Forecast by Country (2027-2032) Table 192. Latin America Multiple Sclerosis (MS) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 193. Latin America Multiple Sclerosis (MS) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 194. Latin America Multiple Sclerosis (MS) Drugs Market Share by Country (2021-2026) Table 195. Latin America Multiple Sclerosis (MS) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 196. Latin America Multiple Sclerosis (MS) Drugs Market Share Forecast by Country (2027-2032) Table 197. Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 198. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026) & (W Units) Table 199. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2021-2026) Table 200. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2027-2032) & (W Units) Table 201. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Market Share Forecast by Country (2027-2032) Table 202. Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 203. Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size by Country (2021-2026) & (US$ Million) Table 204. Middle East and Africa Multiple Sclerosis (MS) Drugs Market Share by Country (2021-2026) Table 205. Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 206. Middle East and Africa Multiple Sclerosis (MS) Drugs Market Share Forecast by Country (2027-2032) Table 207. Key Raw Materials Table 208. Raw Materials Key Suppliers Table 209. Multiple Sclerosis (MS) Drugs Distributors List Table 210. Multiple Sclerosis (MS) Drugs Customers List Table 211. Research Programs/Design for This Report Table 212. Authors List of This Report Table 213. Secondary Sources Table 214. Primary Sources List of Figures Figure 1. Multiple Sclerosis (MS) Drugs Image Figure 2. Global Multiple Sclerosis (MS) Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multiple Sclerosis (MS) Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Multiple Sclerosis (MS) Drugs Sales (2021-2032) & (W Units) Figure 5. Copaxone (Glatiramer Acetate, Copolymer 1) Image Figure 6. Global Copaxone (Glatiramer Acetate, Copolymer 1) Sales YoY Growth (2021-2032) & (W Units) Figure 7. Firategrast (Sb683699, T-0047) Image Figure 8. Global Firategrast (Sb683699, T-0047) Sales YoY Growth (2021-2032) & (W Units) Figure 9. Gilenya (Fingolimod, Fty720) Image Figure 10. Global Gilenya (Fingolimod, Fty720) Sales YoY Growth (2021-2032) & (W Units) Figure 11. Tecfidera (Dimethyl Fumarate) Image Figure 12. Global Tecfidera (Dimethyl Fumarate) Sales YoY Growth (2021-2032) & (W Units) Figure 13. Aubagio (Teriflunomide) Image Figure 14. Global Aubagio (Teriflunomide) Sales YoY Growth (2021-2032) & (W Units) Figure 15. Siponimod (Baf312) Image Figure 16. Global Siponimod (Baf312) Sales YoY Growth (2021-2032) & (W Units) Figure 17. Novantrone (Mitoxantrone) Image Figure 18. Global Novantrone (Mitoxantrone) Sales YoY Growth (2021-2032) & (W Units) Figure 19. Others Image Figure 20. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 21. Global Multiple Sclerosis (MS) Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 22. Global Multiple Sclerosis (MS) Drugs Market Share by Type 2025 VS 2032 Figure 23. North America Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Type in 2025 Figure 24. North America Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Type in 2025 Figure 25. Europe Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Type in 2025 Figure 26. Europe Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Type in 2025 Figure 27. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Type in 2025 Figure 28. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Type in 2025 Figure 29. Latin America Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Type in 2025 Figure 30. Latin America Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Type in 2025 Figure 31. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Type in 2025 Figure 32. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Type in 2025 Figure 33. Global Top 5 and 10 Multiple Sclerosis (MS) Drugs Players Market Share by Revenue in 2025 Figure 34. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 35. PPMS Image Figure 36. Global PPMS Sales YoY Growth (2021-2032) & (W Units) Figure 37. PRMS Image Figure 38. Global PRMS Sales YoY Growth (2021-2032) & (W Units) Figure 39. RRMS Image Figure 40. Global RRMS Sales YoY Growth (2021-2032) & (W Units) Figure 41. SPMS Image Figure 42. Global SPMS Sales YoY Growth (2021-2032) & (W Units) Figure 43. Global Multiple Sclerosis (MS) Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 44. Global Multiple Sclerosis (MS) Drugs Market Share by Application 2025 VS 2032 Figure 45. North America Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Application in 2025 Figure 46. North America Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Application in 2025 Figure 47. Europe Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Application in 2025 Figure 48. Europe Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Application in 2025 Figure 49. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Application in 2025 Figure 50. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Application in 2025 Figure 51. Latin America Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Application in 2025 Figure 52. Latin America Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Application in 2025 Figure 53. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Market Share in Volume by Application in 2025 Figure 54. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Market Share in Value by Application in 2025 Figure 55. North America Multiple Sclerosis (MS) Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 56. North America Multiple Sclerosis (MS) Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. North America Multiple Sclerosis (MS) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. North America Multiple Sclerosis (MS) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Multiple Sclerosis (MS) Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 60. Europe Multiple Sclerosis (MS) Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Multiple Sclerosis (MS) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Europe Multiple Sclerosis (MS) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 64. Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Multiple Sclerosis (MS) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Asia-Pacific Multiple Sclerosis (MS) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Latin America Multiple Sclerosis (MS) Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 68. Latin America Multiple Sclerosis (MS) Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Latin America Multiple Sclerosis (MS) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Latin America Multiple Sclerosis (MS) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 72. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 73. Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 74. Middle East and Africa Multiple Sclerosis (MS) Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 75. Multiple Sclerosis (MS) Drugs Value Chain Figure 76. Key Raw Materials Price Figure 77. Manufacturing Cost Structure Figure 78. Multiple Sclerosis (MS) Drugs Production Mode & Process Figure 79. Direct Comparison with Distribution Share Figure 80. Distributors Profiles Figure 81. Years Considered Figure 82. Research Process Figure 83. Key Executives Interviewed

Scope & coverage.

Types
  • Copaxone (Glatiramer Acetate, Copolymer 1)
  • Firategrast (Sb683699, T-0047)
  • Gilenya (Fingolimod, Fty720)
  • Tecfidera (Dimethyl Fumarate)
  • Aubagio (Teriflunomide)
  • Siponimod (Baf312)
  • Novantrone (Mitoxantrone)
  • Others
Applications
  • PPMS
  • PRMS
  • RRMS
  • SPMS
Companies covered
  • Eli Lilly
  • Bayer AG
  • Innate Immunotherapeutics
  • Gw Pharmaceuticals
  • Glaxosmithkline
  • Genzyme
  • Genmab
  • Five Prime Therapeutics
  • Fast Forward Llc
  • Daiichi Sankyo
  • Cinnagen
  • Biogen Idec
  • Bayhill Therapeutics
  • Artielle Immunotherapeutics
  • Apitope
  • Antisense Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Multiple Sclerosis (MS) Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Multiple Sclerosis (MS) Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Multiple Sclerosis (MS) Drugs Market by Type
  6. 1.3.1 Copaxone (Glatiramer Acetate, Copolymer 1)
  7. 1.3.2 Firategrast (Sb683699, T-0047)
  8. 1.3.3 Gilenya (Fingolimod, Fty720)
  9. 1.3.4 Tecfidera (Dimethyl Fumarate)
  10. 1.3.5 Aubagio (Teriflunomide)
  11. 1.3.6 Siponimod (Baf312)
  12. 1.3.7 Novantrone (Mitoxantrone)
  13. 1.3.8 Others
  14. 1.4 Global Multiple Sclerosis (MS) Drugs Market Size by Type
  15. 1.4.1 Global Multiple Sclerosis (MS) Drugs Market Size Overview by Type (2021-2032)
  16. 1.4.2 Global Multiple Sclerosis (MS) Drugs Historic Market Size Review by Type (2021-2026)
  17. 1.4.3 Global Multiple Sclerosis (MS) Drugs Forecasted Market Size by Type (2027-2032)
  18. 1.5 Key Regions Market Size by Type
  19. 1.5.1 North America Multiple Sclerosis (MS) Drugs Sales Breakdown by Type (2021-2026)
  20. 1.5.2 Europe Multiple Sclerosis (MS) Drugs Sales Breakdown by Type (2021-2026)
  21. 1.5.3 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Breakdown by Type (2021-2026)
  22. 1.5.4 South America Multiple Sclerosis (MS) Drugs Sales Breakdown by Type (2021-2026)
  23. 1.5.5 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Multiple Sclerosis (MS) Drugs Industry Trends
  2. 2.2 Multiple Sclerosis (MS) Drugs Industry Drivers
  3. 2.3 Multiple Sclerosis (MS) Drugs Industry Opportunities and Challenges
  4. 2.4 Multiple Sclerosis (MS) Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Multiple Sclerosis (MS) Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Multiple Sclerosis (MS) Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Multiple Sclerosis (MS) Drugs Price (2021-2026)
  4. 3.4 Global Multiple Sclerosis (MS) Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Multiple Sclerosis (MS) Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Multiple Sclerosis (MS) Drugs Company, Product Type & Application
  7. 3.7 Global Multiple Sclerosis (MS) Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Multiple Sclerosis (MS) Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Multiple Sclerosis (MS) Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Multiple Sclerosis (MS) Drugs Tier 1, Tier 2, and Tier 3
4 Multiple Sclerosis (MS) Drugs Regional Status and Outlook
  1. 4.1 Global Multiple Sclerosis (MS) Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Multiple Sclerosis (MS) Drugs Historic Market Size by Region
  3. 4.2.1 Global Multiple Sclerosis (MS) Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Multiple Sclerosis (MS) Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Multiple Sclerosis (MS) Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Multiple Sclerosis (MS) Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Multiple Sclerosis (MS) Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Multiple Sclerosis (MS) Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Multiple Sclerosis (MS) Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Multiple Sclerosis (MS) Drugs by Application
  1. 5.1 Multiple Sclerosis (MS) Drugs Market by Application
  2. 5.1.1 PPMS
  3. 5.1.2 PRMS
  4. 5.1.3 RRMS
  5. 5.1.4 SPMS
  6. 5.2 Global Multiple Sclerosis (MS) Drugs Market Size by Application
  7. 5.2.1 Global Multiple Sclerosis (MS) Drugs Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Multiple Sclerosis (MS) Drugs Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Multiple Sclerosis (MS) Drugs Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Multiple Sclerosis (MS) Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Multiple Sclerosis (MS) Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Multiple Sclerosis (MS) Drugs Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Eli Lilly
  2. 6.1.1 Eli Lilly Company Information
  3. 6.1.2 Eli Lilly Business Overview
  4. 6.1.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Eli Lilly Multiple Sclerosis (MS) Drugs Product Portfolio
  6. 6.1.5 Eli Lilly Recent Developments
  7. 6.2 Bayer AG
  8. 6.2.1 Bayer AG Company Information
  9. 6.2.2 Bayer AG Business Overview
  10. 6.2.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Bayer AG Multiple Sclerosis (MS) Drugs Product Portfolio
  12. 6.2.5 Bayer AG Recent Developments
  13. 6.3 Innate Immunotherapeutics
  14. 6.3.1 Innate Immunotherapeutics Company Information
  15. 6.3.2 Innate Immunotherapeutics Business Overview
  16. 6.3.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  18. 6.3.5 Innate Immunotherapeutics Recent Developments
  19. 6.4 Gw Pharmaceuticals
  20. 6.4.1 Gw Pharmaceuticals Company Information
  21. 6.4.2 Gw Pharmaceuticals Business Overview
  22. 6.4.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Portfolio
  24. 6.4.5 Gw Pharmaceuticals Recent Developments
  25. 6.5 Glaxosmithkline
  26. 6.5.1 Glaxosmithkline Company Information
  27. 6.5.2 Glaxosmithkline Business Overview
  28. 6.5.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Portfolio
  30. 6.5.5 Glaxosmithkline Recent Developments
  31. 6.6 Genzyme
  32. 6.6.1 Genzyme Company Information
  33. 6.6.2 Genzyme Business Overview
  34. 6.6.3 Genzyme Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Genzyme Multiple Sclerosis (MS) Drugs Product Portfolio
  36. 6.6.5 Genzyme Recent Developments
  37. 6.7 Genmab
  38. 6.7.1 Genmab Company Information
  39. 6.7.2 Genmab Business Overview
  40. 6.7.3 Genmab Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Genmab Multiple Sclerosis (MS) Drugs Product Portfolio
  42. 6.7.5 Genmab Recent Developments
  43. 6.8 Five Prime Therapeutics
  44. 6.8.1 Five Prime Therapeutics Company Information
  45. 6.8.2 Five Prime Therapeutics Business Overview
  46. 6.8.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  48. 6.8.5 Five Prime Therapeutics Recent Developments
  49. 6.9 Fast Forward Llc
  50. 6.9.1 Fast Forward Llc Company Information
  51. 6.9.2 Fast Forward Llc Business Overview
  52. 6.9.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Portfolio
  54. 6.9.5 Fast Forward Llc Recent Developments
  55. 6.10 Daiichi Sankyo
  56. 6.10.1 Daiichi Sankyo Company Information
  57. 6.10.2 Daiichi Sankyo Business Overview
  58. 6.10.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Portfolio
  60. 6.10.5 Daiichi Sankyo Recent Developments
  61. 6.11 Cinnagen
  62. 6.11.1 Cinnagen Company Information
  63. 6.11.2 Cinnagen Business Overview
  64. 6.11.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Cinnagen Multiple Sclerosis (MS) Drugs Product Portfolio
  66. 6.11.5 Cinnagen Recent Developments
  67. 6.12 Biogen Idec
  68. 6.12.1 Biogen Idec Company Information
  69. 6.12.2 Biogen Idec Business Overview
  70. 6.12.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Biogen Idec Multiple Sclerosis (MS) Drugs Product Portfolio
  72. 6.12.5 Biogen Idec Recent Developments
  73. 6.13 Bayhill Therapeutics
  74. 6.13.1 Bayhill Therapeutics Company Information
  75. 6.13.2 Bayhill Therapeutics Business Overview
  76. 6.13.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  78. 6.13.5 Bayhill Therapeutics Recent Developments
  79. 6.14 Artielle Immunotherapeutics
  80. 6.14.1 Artielle Immunotherapeutics Company Information
  81. 6.14.2 Artielle Immunotherapeutics Business Overview
  82. 6.14.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  84. 6.14.5 Artielle Immunotherapeutics Recent Developments
  85. 6.15 Apitope
  86. 6.15.1 Apitope Company Information
  87. 6.15.2 Apitope Business Overview
  88. 6.15.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Apitope Multiple Sclerosis (MS) Drugs Product Portfolio
  90. 6.15.5 Apitope Recent Developments
  91. 6.16 Antisense Therapeutics
  92. 6.16.1 Antisense Therapeutics Company Information
  93. 6.16.2 Antisense Therapeutics Business Overview
  94. 6.16.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  96. 6.16.5 Antisense Therapeutics Recent Developments
7 North America by Country
  1. 7.1 North America Multiple Sclerosis (MS) Drugs Sales by Country
  2. 7.1.1 North America Multiple Sclerosis (MS) Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Multiple Sclerosis (MS) Drugs Market Size by Country
  6. 7.2.1 North America Multiple Sclerosis (MS) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Multiple Sclerosis (MS) Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Multiple Sclerosis (MS) Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Multiple Sclerosis (MS) Drugs Sales by Country
  2. 8.1.1 Europe Multiple Sclerosis (MS) Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Multiple Sclerosis (MS) Drugs Market Size by Country
  6. 8.2.1 Europe Multiple Sclerosis (MS) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Multiple Sclerosis (MS) Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Multiple Sclerosis (MS) Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Multiple Sclerosis (MS) Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Multiple Sclerosis (MS) Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Multiple Sclerosis (MS) Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Multiple Sclerosis (MS) Drugs Sales by Country
  2. 10.1.1 South America Multiple Sclerosis (MS) Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Multiple Sclerosis (MS) Drugs Market Size by Country
  6. 10.2.1 South America Multiple Sclerosis (MS) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Multiple Sclerosis (MS) Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Multiple Sclerosis (MS) Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Multiple Sclerosis (MS) Drugs Value Chain Analysis
  2. 12.1.1 Multiple Sclerosis (MS) Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Multiple Sclerosis (MS) Drugs Production Mode & Process
  7. 12.2 Multiple Sclerosis (MS) Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Multiple Sclerosis (MS) Drugs Distributors
  10. 12.2.3 Multiple Sclerosis (MS) Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst